Brief: Cstone Pharmaceuticals Says China's NMPA Accepted & Granted Priority Review To Supplemental New Drug Application For Sugemalimab
13/09/2022 02:46
Sept 13 (Reuters) - CStone Pharmaceuticals 2616.HK :
* CHINA'S NMPA HAS ACCEPTED & GRANTED PRIORITY REVIEW TO
SUPPLEMENTAL NEW DRUG APPLICATION FOR SUGEMALIMAB
* APPLICATION FOR SUGEMALIMAB IN TREATMENT OF PATIENTS WITH
RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026